While TROP2 expression was prognostic in univariable analyses of the overall cohort (e.g. for disease‐free survival, p < 0.001), it exhibited distinct variations among important clinicopathological subgroups (e.g. right‐ versus left‐sided CRC, microsatellite stable versus unstable CRC, Union for International Cancer Control [UICC] stages) and lost its significance in multivariable analyses that included stage and CRC histopathology. The gene discussed is TACSTD2; the disease is colorectal carcinoma.